Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.130
-0.090 (-4.05%)
Aug 29, 2025, 4:00 PM - Market closed
Adagene Revenue
Adagene had revenue of $103.20K in the twelve months ending June 30, 2025, down -87.35% year-over-year. In the year 2024, Adagene had annual revenue of $103.20K, down -99.43%.
Revenue (ttm)
$103.20K
Revenue Growth
-87.35%
P/S Ratio
986.43
Revenue / Employee
$748
Employees
138
Market Cap
100.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ADAG News
- 3 days ago - Adagene to Participate in Two Investor Conferences in September - GlobeNewsWire
- 17 days ago - Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewsWire
- 7 weeks ago - Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewsWire
- 2 months ago - Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewsWire
- 3 months ago - Adagene to Present at Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 3 months ago - Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 4 months ago - Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewsWire